“Our QUELIMMUNE net revenue in the first quarter was $495,000, a solid increase of 69% from the first quarter of last year,” said (Senior Vice President of Commercial & Business Operations Tim Varacek ...

Hakeem Fawehinmi, says Nigeria bears the highest global burden of Sickle Cell Disease, with about 150,000 children born ...

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. Approximately 10% of people with ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. Approximately 10 percent of people with SCD in the US live ...

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. Approximately 10 percent of ...

Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the first quarter of 2026, narrower than the Zacks ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected ...

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset reduced a painful complication of sickle cell disease (SCD) in a phase 3 study.